Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Arena Announces $33 Mln Financing - Quick Facts

RELATED NEWS
Trade ARNA now with 
1/11/2012 6:18 AM ET

Arena Pharmaceuticals, Inc. (ARNA: Quote) said it has agreed to sell 9.95 million shares of its common stock at a price of $1.65775 per share, and around 9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization. The closing of the offering is expected to take place on or about January 13, 2012.

The company noted that the preferred stock is convertible into an aggregate of 9.95 million shares of its common stock. Arena expects to receive gross proceeds of around $33 million.

The company stated that it will use $5 million of the proceeds from the offering to prepay a portion of the loan principal that otherwise would have been required to be repaid in June 2013 under the existing Facility Agreement between Arena and Deerfield.

Click here to receive FREE breaking news email alerts for Arena Pharmaceutical Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012. Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Analog Devices, Inc. said that its second quarter profit rose slightly from last year, helped mainly by lower income tax expenses even as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations. However, the company forecast third quarter revenue and earnings below analysts' current consensus estimates.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.